Clarus Therapeutics Holdings, Inc. (CRXTQ)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Clarus Therapeutics Holdings, Inc. (CRXTQ) trades at $0.00 with AI Score 68/100 (Grade B+). Clarus Therapeutics Holdings, Inc. Market cap: $72,829, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for CRXTQ: CRXTQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CRXTQ against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
CRXTQ: 4/7 perspectives are bullish. Dominant signal: Seth Klarman bullish.
How is this calculated? →Clarus Therapeutics Holdings, Inc. (CRXTQ) Healthcare & Pipeline Overview
Clarus Therapeutics Holdings, Inc. focuses on developing and commercializing oral testosterone replacement therapy in the U.S. with its product, JATENZO. The company also holds licensing agreements for therapies addressing inflammatory breast disease and CoQ10 deficiencies, operating from Northbrook, Illinois, while navigating Chapter 11 reorganization proceedings initiated in September 2022.
What Is the Investment Thesis for CRXTQ?
Clarus Therapeutics Holdings, Inc.'s investment profile is significantly shaped by its core asset, JATENZO, an oral testosterone replacement therapy, and its strategic licensing agreements, all set against the backdrop of its ongoing Chapter 11 bankruptcy proceedings initiated in September 2022. The thesis centers on the inherent value of its intellectual property and product portfolio, despite the current financial distress. JATENZO addresses a defined market of hypogonadal men, offering an oral formulation that distinguishes it within the testosterone replacement therapy landscape. Additionally, the company's licensing agreements with HavaH Therapeutics for inflammatory breast disease and McGill University for CoQ10 deficiencies represent potential future value streams, contingent on successful development and commercialization, and the outcome of the bankruptcy. The company's gross margin of 80.5% indicates strong product-level profitability, though this is overshadowed by a substantial negative profit margin of -404.9% and a market capitalization of 73K, reflecting its distressed financial state. The high beta of 1.68 suggests significant volatility. The primary value driver for any potential future entity or asset acquirer would be the successful navigation of the bankruptcy process and the subsequent realization of JATENZO's market potential or the advancement of its licensed therapeutic programs.
Based on FMP financials and quantitative analysis
CRXTQ Key Highlights
- Market Capitalization: $0.00 billion, reflecting its current financial distress and Chapter 11 reorganization status.
- Profit Margin: -404.9%, indicating significant operational losses relative to revenue.
- Gross Margin: 80.5%, demonstrating strong profitability at the product cost level for its offerings.
- Beta: 1.68, suggesting higher volatility compared to the broader market.
- Dividend Yield: None, as the company does not currently distribute dividends to shareholders.
Who Are CRXTQ's Competitors?
CRXTQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ORINY Orion Oyj | $38.86 | +0.00% | $21.87B | 64 |
| MRK Merck & Co., Inc. | $126.78 | -2.15% | $313.12B | 64 |
| ORINF Orion Oyj | $82.75 | +0.00% | $11.66B | 63 |
| AZN AstraZeneca PLC | $190.16 | -2.56% | $294.91B | 61 |
| GSK GSK plc | $53.20 | -0.87% | $106.54B | 61 |
| RHHBY Roche Holding AG | $51.62 | -2.68% | $332.48B | 61 |
| AZNCF AstraZeneca PLC | $189.90 | -1.35% | $294.40B | 60 |
| AMGN Amgen Inc. | $365.01 | -2.44% | $197.00B | 59 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CRXTQ's Key Strengths?
- Proprietary oral testosterone replacement therapy, JATENZO, offering a convenient delivery method.
- Strategic licensing agreements with HavaH Therapeutics and McGill University for diversified therapeutic areas.
- High gross margin of 80.5% on its product, indicating strong unit economics.
What Are CRXTQ's Weaknesses?
- Ongoing Chapter 11 bankruptcy proceedings, creating significant financial and operational uncertainty.
- Substantial negative profit margin of -404.9%, reflecting severe financial losses.
- Very small employee base (16 employees) for a pharmaceutical company, potentially limiting R&D and commercialization capacity.
- Market capitalization of 73K, indicating a distressed valuation.
What Could Drive CRXTQ Stock Higher?
- Resolution of Chapter 11 Bankruptcy Proceedings: The primary ongoing catalyst is the progression and eventual resolution of the voluntary petition for reorganization under Chapter 11, filed on September 5, 2022. The outcome of these proceedings, whether it leads to a successful reorganization, asset sale, or liquidation, will fundamentally determine the future of the company and the value of its assets.
- Strategic Decisions Regarding JATENZO: Decisions made within the bankruptcy process concerning the future of JATENZO, such as its continued commercialization, sale, or transfer of rights, will serve as significant catalysts. The product's market presence and potential for continued revenue generation are key considerations.
- Updates on Licensing Agreement Status: Any public announcements or court filings regarding the status of the licensing agreements with HavaH Therapeutics and McGill University, including their continuation, termination, or transfer, could act as catalysts, as these agreements represent potential future value.
What Are the Key Risks for CRXTQ?
- Chapter 11 Bankruptcy Outcome: The most significant ongoing risk is the uncertain outcome of the Chapter 11 reorganization. This could result in the complete loss of value for existing equity holders, liquidation of assets, or a highly dilutive restructuring plan.
- Severe Financial Distress: The company's reported negative profit margin of -404.9% and 73K market capitalization indicate profound financial distress, posing an ongoing risk to its operational viability and ability to emerge from bankruptcy.
- Loss of Intellectual Property Value: In a bankruptcy scenario, there is a risk that the value of the company's intellectual property, including JATENZO and its licensing agreements, may be significantly diminished or lost through forced sales or termination of agreements.
- Regulatory and Market Challenges: Even if the company's assets are acquired or reorganized, they would still face inherent risks within the pharmaceutical industry, including intense competition, potential adverse regulatory actions, and challenges in market adoption for its products.
What Are the Growth Opportunities for CRXTQ?
- Expansion of JATENZO's Market Penetration: JATENZO, as an oral testosterone undecanoate formulation, addresses the significant market of hypogonadal men seeking convenient treatment options. The oral delivery method offers a distinct advantage over traditional injectables or gels, potentially improving patient adherence and preference. The market for testosterone replacement therapy continues to grow driven by increased diagnosis and an aging population. Should the company's assets be successfully restructured or acquired, there remains an opportunity to aggressively market JATENZO to a broader physician base and patient population, leveraging its unique formulation to capture a larger share of the U.S. TRT market.
- Development of HavaH Therapeutics Licensed Products: Clarus Therapeutics holds a licensing agreement with HavaH Therapeutics for products designed to treat inflammatory breast disease and certain forms of breast cancer. This represents a substantial growth opportunity by diversifying the company's therapeutic portfolio beyond endocrinology into oncology, a market segment with high unmet medical needs and significant revenue potential. Successful development, clinical trials, and regulatory approval of these androgen therapies could unlock new revenue streams and establish Clarus, or its successor, in a critical disease area, offering substantial long-term growth prospects.
- Commercialization of McGill University's CoQ10 Technology: The licensing agreement with The Royal Institution for the Advancement of Learning/McGill University for technology treating CoQ10 deficiencies presents another distinct avenue for growth. CoQ10 deficiencies are associated with various health conditions, and a proprietary technology to address these could tap into a growing market for metabolic and mitochondrial health solutions. Developing and commercializing this technology would allow Clarus, or its assets, to enter a new therapeutic area with potentially broad applications, providing diversification and a new source of intellectual property-driven revenue.
- Strategic Partnerships and Asset Divestiture: Given the company's Chapter 11 status, a significant growth opportunity lies in the strategic sale or partnership of its valuable assets, including JATENZO and its licensing agreements. These assets, particularly JATENZO's oral TRT formulation, hold inherent value that could be maximized by a larger pharmaceutical entity with greater resources for marketing, distribution, and pipeline development. Such a transaction could unlock the underlying value of Clarus's intellectual property and product portfolio, ensuring their continued development and commercialization under new stewardship.
- Innovation in Oral Drug Delivery: Clarus Therapeutics' expertise in developing an oral soft gel formulation for testosterone undecanoate highlights its capability in oral drug delivery technology. This core competency could be leveraged for future product development or out-licensing opportunities beyond its current pipeline. The pharmaceutical industry continually seeks improved patient compliance and convenience through innovative delivery methods. Applying this expertise to other challenging compounds or therapeutic areas could represent a long-term growth vector, either through internal R&D or collaborative ventures, expanding the company's technological footprint.
What Opportunities Does CRXTQ Have?
- Potential for successful reorganization or acquisition of assets, allowing JATENZO and licensed programs to continue development under new stewardship.
- Growth in the broader testosterone replacement therapy market, driven by increasing diagnosis and patient demand for oral options.
- Advancement and commercialization of licensed products for inflammatory breast disease/cancer and CoQ10 deficiencies, opening new revenue streams.
What Threats Does CRXTQ Face?
- Uncertain outcome of Chapter 11 bankruptcy, potentially leading to liquidation or significant dilution for existing shareholders.
- Intense competition in the testosterone replacement therapy market from established pharmaceutical companies with diverse product offerings.
- Regulatory hurdles and clinical trial risks associated with developing new pharmaceutical products from licensing agreements.
- Market perception challenges and loss of confidence due to bankruptcy filing.
What Are CRXTQ's Competitive Advantages?
- Oral Formulation of JATENZO: The soft gel oral formulation of testosterone undecanoate offers a differentiated delivery method compared to traditional injectables or topical gels, potentially enhancing patient convenience and adherence.
- Proprietary Licensing Agreements: Exclusive licensing agreements with HavaH Therapeutics and McGill University provide access to specific technologies and therapeutic candidates in oncology and metabolic health, diversifying its intellectual property portfolio.
- Regulatory Approval for JATENZO: JATENZO has successfully navigated the U.S. regulatory approval process, representing a significant hurdle overcome and a validated product on the market.
What Does CRXTQ Do?
Clarus Therapeutics Holdings, Inc., founded in 2003 and headquartered in Northbrook, Illinois, operates as a pharmaceutical company primarily dedicated to the development and commercialization of oral testosterone replacement therapy within the United States market. Its flagship product, JATENZO, is a soft gel oral formulation of testosterone undecanoate specifically designed for treating men diagnosed with hypogonadism. This product represents a key component of the company's efforts to provide convenient and effective therapeutic options in the androgen deficiency space. Beyond its core testosterone replacement therapy, Clarus Therapeutics has strategically expanded its potential therapeutic reach through various licensing agreements. The company maintains a licensing agreement with HavaH Therapeutics, which focuses on developing products for androgen therapies targeting inflammatory breast disease and certain forms of breast cancer, indicating a potential diversification into oncology-related treatments. Furthermore, Clarus Therapeutics holds a license agreement with The Royal Institution for the Advancement of Learning/McGill University. This collaboration aims to develop and commercialize McGill's proprietary technology, which is intended to treat conditions associated with CoQ10 deficiencies in humans, suggesting an interest in metabolic or mitochondrial health areas. Despite its established product and pipeline agreements, Clarus Therapeutics Holdings, Inc., along with an affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware on September 5, 2022, significantly impacting its operational and financial trajectory. The company currently employs 16 individuals.
What Products and Services Does CRXTQ Offer?
- Develops and commercializes JATENZO, an oral testosterone replacement therapy.
- Offers JATENZO, a soft gel oral formulation of testosterone undecanoate, for hypogonadal men.
- Holds a licensing agreement with HavaH Therapeutics for androgen therapies targeting inflammatory breast disease and certain breast cancers.
- Maintains a license agreement with McGill University for technology to treat CoQ10 deficiencies.
- Focuses on the U.S. market for its primary product.
- Operates within the pharmaceutical sector, specializing in therapeutic drug development.
- Manages a small team of 16 employees from its Northbrook, Illinois headquarters.
How Does CRXTQ Make Money?
- Product Sales: Generates revenue primarily through the commercialization and sale of its oral testosterone replacement therapy, JATENZO, in the United States market.
- Licensing Agreements: Potentially generates future revenue through milestone payments, royalties, or other commercial terms associated with its licensing agreements for therapies in inflammatory breast disease/cancer and CoQ10 deficiencies.
- Pharmaceutical Development: Invests in the research, development, and regulatory approval processes for its therapeutic products to bring them to market.
What Industry Does CRXTQ Operate In?
Clarus Therapeutics Holdings, Inc. operates within the highly regulated and competitive Drug Manufacturers - General industry, specifically focusing on the niche market of oral testosterone replacement therapy. The broader healthcare sector, particularly pharmaceuticals, is characterized by extensive research and development cycles, stringent regulatory approval processes, and significant market demand driven by demographic shifts and increasing prevalence of chronic conditions. The market for testosterone replacement therapy (TRT) has seen growth, with a preference for convenient and less invasive administration methods. Oral formulations, such as Clarus's JATENZO, aim to differentiate themselves from traditional injectable or topical applications. The competitive landscape includes established pharmaceutical companies with various TRT products, as well as emerging biotechs. Clarus's positioning is further complicated by its current Chapter 11 bankruptcy filing, which places its future market participation and competitive standing in a state of uncertainty, despite its innovative product and licensing agreements in other therapeutic areas like inflammatory breast disease and CoQ10 deficiencies.
Who Are CRXTQ's Key Customers?
- Men diagnosed with hypogonadism who require testosterone replacement therapy.
- Healthcare providers, including endocrinologists and general practitioners, who prescribe testosterone replacement therapies.
- Potentially, patient populations suffering from inflammatory breast disease, certain forms of breast cancer, and CoQ10 deficiencies, pending development and commercialization of licensed products.
Company Profile
Clarus Therapeutics Holdings, Inc. operates in the Drug Manufacturers - General industry within the Healthcare sector. It is headquartered in Northbrook, US. The company is led by CEO Robert E. Dudley. CRXTQ has traded publicly since 2021.
How Clarus Therapeutics Holdings, Inc. Is Valued
Clarus Therapeutics Holdings, Inc. carries a market capitalization of 73K, placing it in the micro-cap category. Relative to its peer group, CRXTQ's quantitative score of 68/100 is roughly in line with the peer average of 63/100.
CRXTQ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Proprietary oral testosterone replacement therapy, JATENZO, offering a convenient delivery method.
- Strategic licensing agreements with HavaH Therapeutics and McGill University for diversified therapeutic areas.
- High gross margin of 80.5% on its product, indicating strong unit economics.
- Ongoing: Resolution of Chapter 11 Bankruptcy Proceedings: The primary ongoing catalyst is the progression and eventual resolution of the voluntary petition for reorganization under Chapter 11, filed on September 5, 20…
Bear Case
- Ongoing Chapter 11 bankruptcy proceedings, creating significant financial and operational uncertainty.
- Substantial negative profit margin of -404.9%, reflecting severe financial losses.
- Very small employee base (16 employees) for a pharmaceutical company, potentially limiting R&D and commercialization capacity.
- Market capitalization of 73K, indicating a distressed valuation.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
CRXTQ Latest News
No recent news available for CRXTQ.
CRXTQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CRXTQ.
Price Targets
Wall Street price target analysis for CRXTQ.
CRXTQ MoonshotScore
What does this score mean?
The MoonshotScore rates CRXTQ's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Robert E. Dudley
Chief Executive Officer
The specific career history, educational background, and previous professional roles of Robert E. Dudley are not detailed in the provided source data. He is identified as managing the company's 16 employees, indicating a central leadership role within the organization. Further information regarding his professional journey prior to his current position at Clarus Therapeutics Holdings, Inc. is unknown.
Track Record: Details regarding Robert E. Dudley's specific achievements, strategic decisions, or key company milestones directly attributable to his leadership at Clarus Therapeutics Holdings, Inc. are not provided in the available information. His role involves overseeing the company's operations and strategic direction, particularly during its current Chapter 11 reorganization process. The impact of his leadership on the company's product development and commercialization efforts, including JATENZO, is not explicitly documented.
CRXTQ OTC Market Information
Clarus Therapeutics Holdings, Inc. trades on the OTC Other tier of the OTC market. This tier is typically for companies that do not meet the reporting requirements for OTCQX or OTCQB, or that are in financial distress, such as bankruptcy. Unlike exchanges like NYSE or NASDAQ, which have stringent listing requirements including minimum share prices, market capitalization, and financial reporting standards, the OTC market has varying tiers with less demanding criteria. The "OTC Other" designation often implies a higher level of risk and less transparency compared to higher OTC tiers or major exchanges.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Lack of transparent and consistent financial reporting due to "Unknown" disclosure status.
- Extremely low liquidity and wide bid-ask spreads, making trading difficult and potentially costly.
- Higher susceptibility to fraud and manipulation due to less stringent oversight compared to major exchanges.
- Limited analyst coverage and institutional interest, leading to less public information and price discovery.
- Significant price volatility due to low trading volume and speculative trading.
- Verify the company's current status in the Chapter 11 bankruptcy proceedings and review all available court filings.
- Attempt to locate any recent financial statements or operational updates, despite the "Unknown" disclosure status.
- Research the underlying assets, particularly JATENZO and the licensing agreements, for their inherent value and market potential.
- Assess the management team's plans for reorganization or asset disposition, if publicly available.
- Investigate any news or press releases from the company or bankruptcy court for material developments.
- Understand the legal implications for existing shareholders in a Chapter 11 reorganization.
- The company was founded in 2003, indicating a history of operation prior to its current distress.
- Development and commercialization of a specific FDA-approved product, JATENZO, demonstrates past operational capability.
- Established licensing agreements with reputable entities like HavaH Therapeutics and McGill University suggest legitimate intellectual property and collaborations.
- Headquartered in Northbrook, Illinois, with a physical presence.
CRXTQ Healthcare Stock FAQ
What does Clarus Therapeutics Holdings, Inc. do?
Clarus Therapeutics Holdings, Inc. is a pharmaceutical company founded in 2003, primarily focused on the development and commercialization of oral testosterone replacement therapy in the United States. Its flagship product is JATENZO, a soft gel oral formulation of testosterone undecanoate designed to treat men with hypogonadism. Beyond this core product, the company has expanded its potential therapeutic scope through strategic licensing agreements. These include a partnership with HavaH Therapeutics for androgen therapies addressing inflammatory breast disease and certain forms of breast cancer, and another with The Royal Institution for the Advancement of Learning/McGill University to develop technology for treating conditions related to CoQ10 deficiencies. The company operates from Northbrook, Illinois, with a team of 16 employees.
How does Clarus Therapeutics Holdings, Inc. navigate regulatory approval processes?
Clarus Therapeutics Holdings, Inc. has successfully navigated the U.S. regulatory approval process for its primary product, JATENZO, an oral testosterone replacement therapy. This indicates the company's capability in managing the rigorous requirements set by regulatory bodies like the FDA for pharmaceutical products. The approval of JATENZO demonstrates adherence to clinical trial protocols, safety, and efficacy standards. For its licensed products, such as those from HavaH Therapeutics for breast disease and McGill University for CoQ10 deficiencies, the company, or any successor entity, would need to guide these candidates through their respective preclinical and clinical development phases, culminating in regulatory submissions. The process involves extensive data generation, adherence to Good Clinical Practice (GCP) and Good Manufacturing Practice (GMP), and ongoing post-market surveillance to ensure compliance and patient safety.
What are the main risks for CRXTQ?
The most significant risk for Clarus Therapeutics Holdings, Inc. (CRXTQ) stems from its ongoing Chapter 11 bankruptcy proceedings, initiated in September 2022. This process introduces substantial uncertainty regarding the company's future, potentially leading to liquidation, significant dilution for existing shareholders, or a complete loss of investment value. Financially, the company exhibits severe distress, evidenced by a negative profit margin of -404.9% and a 73K market capitalization. Beyond bankruptcy, inherent pharmaceutical industry risks include intense competition in the testosterone replacement therapy market, potential for adverse regulatory decisions, and the high costs and uncertainties associated with clinical development and commercialization of its licensed therapeutic programs. The "Unknown" disclosure status for its OTC listing also poses a risk by limiting access to timely and comprehensive financial information.
What revenue streams does Clarus Therapeutics Holdings, Inc. have in healthcare?
Clarus Therapeutics Holdings, Inc. primarily generates revenue through the commercialization and sales of its oral testosterone replacement therapy, JATENZO, within the United States. This product, a soft gel oral formulation of testosterone undecanoate, is prescribed for men with hypogonadism, representing a direct product sales model in the pharmaceutical market. In addition to direct product sales, the company has established licensing agreements that represent potential future revenue streams. These include a partnership with HavaH Therapeutics for androgen therapies targeting inflammatory breast disease and certain forms of breast cancer, and an agreement with McGill University for technology related to CoQ10 deficiencies. While these licensing agreements may involve upfront payments, milestone achievements, or future royalties, their current contribution to revenue is not specified, and their realization is contingent on successful development and commercialization, especially given the company's ongoing Chapter 11 proceedings.
What are the key factors to evaluate for CRXTQ?
Clarus Therapeutics Holdings, Inc. (CRXTQ) holds an AI score of 68/100 (moderate). Not financial advice.
How frequently does CRXTQ data refresh on this page?
CRXTQ prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CRXTQ's recent stock price performance?
Clarus Therapeutics Holdings, Inc. (CRXTQ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary oral testosterone replacement therapy, JATENZO, offering a convenient delivery method. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CRXTQ overvalued or undervalued right now?
Valuing Clarus Therapeutics Holdings, Inc. (CRXTQ) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information regarding CEO background, track record, and specific details on licensing agreement terms or market sizes for growth opportunities was not provided in the source data and has been marked as 'Unknown' or generalized where necessary. Competitor information was not provided, so the array is empty. The company's Chapter 11 bankruptcy filing significantly impacts the interpretation of financial metrics and future prospects.